Lincoln Pharmaceuticals Share Price

NSE
LINCOLN •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Lincoln Pharmaceuticals
Lincoln Pharmaceuticals Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Lincoln Pharmaceuticals Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
42.06% Fall from 52W High
-19.2
Dividend yield 1yr %
Below industry Median
0.3

Lincoln Pharmaceuticals Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Lincoln Pharmaceuticals Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
146.55 Cr
161.21 Cr
147.28 Cr
142.49 Cr
146.45 Cr

Lincoln Pharmaceuticals Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
614.97 Cr
532.78 Cr
482.12 Cr
429.85 Cr
397.53 Cr
371.83 Cr

Lincoln Pharmaceuticals Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
20.77 Cr
26.33 Cr
23.67 Cr
18.6 Cr
28.04 Cr

Lincoln Pharmaceuticals Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
93.3 Cr
72.9 Cr
69.36 Cr
62.25 Cr
51.47 Cr
48.74 Cr
Lincoln Pharmaceuticals Result Highlights
  • Lincoln Pharmaceuticals Ltd reported a 9.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 1.2%.

  • Its expenses for the quarter were down by 7.0% QoQ and up 5.9% YoY.

  • The net profit decreased 21.1% QoQ and decreased 25.9% YoY.

  • The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 10.4 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Lincoln Pharmaceuticals shareholding Pattern

Promoter
49.8%
Foreign Institutions
5%
Public
45.2%
Promoter
49.8%
Foreign Institutions
5.2%
Public
45.1%
Promoter
49.8%
Foreign Institutions
5.2%
Public
45%
Promoter
49.8%
Foreign Institutions
4%
Public
46.2%
Promoter
49.5%
Foreign Institutions
3.9%
Domestic Institutions
0.1%
Public
46.5%
Promoter
49.8%
Foreign Institutions
3.2%
Domestic Institutions
0.1%
Public
46.9%

Lincoln Pharmaceuticals Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
3
Bearish Moving Averages
13
5Day EMA
579.40
10Day EMA
577.40
12Day EMA
575.90
20Day EMA
571.70
26Day EMA
571.70
50Day EMA
589.20
100Day EMA
626.80
200Day EMA
645.60
5Day SMA
586.30
10Day SMA
580.40
20Day SMA
567.00
30Day SMA
560.40
50Day SMA
562.00
100Day SMA
681.40
150Day SMA
675.80
200Day SMA
679.40
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
13862 Rs
30515 Rs
Week Rs
35554 Rs
70168 Rs
Month Rs
29763 Rs
60309 Rs
Resistance & Support
573.97
Pivot
Resistance
First Resistance
582.93
Second Resistance
598.37
Third Resistance
607.33
Support
First Support
558.53
Second support
549.57
Third Support
534.13
Relative Strength Index
48.21
Money Flow Index
55.40
MACD
4.14
MACD Signal
1.16
Average True Range
23.74
Average Directional Index
16.96
Rate of Change (21)
2.89
Rate of Change (125)
-12.46

Lincoln Pharmaceuticals Latest News

23 APR 2025 | Wednesday

Lincoln Pharmaceuticals Ltd - 531633 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

18 APR 2025 | Friday

Lincoln Pharmaceuticals Ltd - 531633 - Intimation Of Change In Email And Website Address Of MUFG Intime India Private Limited, Registrar And Share Transfer Agent (''RTA'') Of The Company

05 APR 2025 | Saturday

Lincoln Pharmaceuticals Ltd - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

View More

Lincoln Pharmaceuticals Company background

Founded in: 1995
Managing director: Mahendra G Patel
Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. 95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The focused area includes antiinfective, respiratory system, gynecology, cardio CNS, antidiabetic, anti malaria, among others.The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals.The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake inhouse testing of its products for better quality control and RD. It came out with a public issue in Feb.96 to partfinance its project.The Company launched Next Generation Progesterone Therapy ProlinSpray during the year 2018. During the year 202122, Lincoln Parenteral Limited, an erstwhile subsidiary, merged with the Company through Scheme of Amalgamation and Lincoln Parenteral Limited ceased to be a subsidiary of the Company. The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022.
Read More

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹566.9 in NSE and ₹565.6 in BSE as on 30/4/2025.

Lincoln Pharmaceuticals share price in the past 1-year return was -6.13. The Lincoln Pharmaceuticals share hit a 1-year low of Rs. 499 and a 1-year high of Rs. 979.5.

The market cap of Lincoln Pharmaceuticals is Rs. 1136.69 Cr. as of 30/4/2025.

The PE ratios of Lincoln Pharmaceuticals is 12.72 as of 30/4/2025.

The PB ratios of Lincoln Pharmaceuticals is 1.77 as of 30/4/2025

You can easily buy Lincoln Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Lincoln Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -